Craig-Liposet-quote-jpg (1)
Doctors are the trusted gatekeepers of patients. They diagnose, prescribe, refer, and provide medical guidance. Acknowledging these relationships by aligning incentives allows local doctors to be the best advocates for their patients.
The Path To “Patient Centric Is Through A Doctor

Patients expect to hear about care options from their trusted healthcare providers.1 Most platforms attempt to reach patients directly, ignoring the existing relationships with treating physicians.

1. CISCRP 2019 Perceptions and Insights Study

MedVector aligns incentives of non-investigator physicians, enabling them to offer clinical trials as a care option from their local practice.

Doc-patient-smiling

  • Unlocks access to the millions of patients behind specialists and other non-referring physicians.
  • Creates greater diversity.
  • Works with most existing study protocols without activating new sites.
  • Is agnostic by design.
  • Eliminates geographic barriers.

The Future of Clinical Trials is Decentralized

The Covid Effect

  • Industry shift to telemedicine has created sustaining change.
  • Increasing public awareness and expectations.
  • 75% of sponsors now incorporating virtual elements into studies.1
  • 73% of sites commit to using telemedicine after pandemic.2

Global Regulatory Support

  • Regulators around the world issued guidance supporting shift to DCT.
  • FDA published commitment supporting decentralized approaches.3

Widespread Industry Support

  • Over 100 pharma, CROs, site networks, advocacy groups, along with FDA have committed to DTC adoption through DTRA.

1. Survey Report: Virtual Trials and the COVID-19 Pandemic, June 2020
2. WCG CenterWatch
3. FDA.gov